Park National Corp’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$983K Sell
17,062
-1,155
-6% -$66.3K 0.03% 200
2026
Q1
$1.1M Sell
18,217
-848
-4% -$49.4K 0.03% 193
2025
Q4
$1.03M Sell
19,065
-113
-0.6% -$5.44K 0.03% 184
2025
Q3
$865K Sell
19,178
-1,110
-5% -$51.8K 0.03% 190
2025
Q2
$939K Sell
20,288
-361
-2% -$17.7K 0.03% 182
2025
Q1
$1.26M Buy
20,649
+274
+1% +$16K 0.05% 161
2024
Q4
$1.15M Sell
20,375
-75
-0.4% -$4.19K 0.04% 164
2024
Q3
$1.06M Sell
20,450
-388
-2% -$18.2K 0.04% 170
2024
Q2
$865K Sell
20,838
-1,284
-6% -$57.5K 0.03% 176
2024
Q1
$1.2M Sell
22,122
-4,743
-18% -$242K 0.05% 158
2023
Q4
$1.38M Sell
26,865
-4,682
-15% -$246K 0.06% 147
2023
Q3
$1.83M Buy
31,547
+3,662
+13% +$224K 0.08% 130
2023
Q2
$1.78M Sell
27,885
-717
-3% -$48.1K 0.08% 134
2023
Q1
$1.98M Buy
28,602
+166
+0.6% +$11.7K 0.09% 124
2022
Q4
$2.05M Sell
28,436
-1,284
-4% -$96.8K 0.09% 126
2022
Q3
$2.11M Buy
29,720
+71
+0.2% +$5.15K 0.11% 106
2022
Q2
$2.28M Sell
29,649
-922
-3% -$70.2K 0.11% 109
2022
Q1
$2.23M Sell
30,571
-1,398
-4% -$93.9K 0.09% 116
2021
Q4
$1.99M Buy
31,969
+2,050
+7% +$120K 0.08% 123
2021
Q3
$1.77M Sell
29,919
-1,840
-6% -$121K 0.07% 128
2021
Q2
$2.12M Sell
31,759
-1,444
-4% -$94.2K 0.09% 121
2021
Q1
$2.1M Sell
33,203
-1,995
-6% -$124K 0.09% 120
2020
Q4
$2.18M Sell
35,198
-794
-2% -$48.8K 0.1% 113
2020
Q3
$2.17M Sell
35,992
-525
-1% -$31.6K 0.11% 105
2020
Q2
$2.15M Buy
36,517
+605
+2% +$36.2K 0.12% 105
2020
Q1
$2M Sell
35,912
-100
-0.3% -$6.11K 0.13% 100
2019
Q4
$2.31M Buy
36,012
+509
+1% +$29.2K 0.12% 107
2019
Q3
$1.8M Buy
35,503
+1,420
+4% +$66.7K 0.1% 121
2019
Q2
$1.55M Sell
34,083
-465
-1% -$21.7K 0.08% 128
2019
Q1
$1.65M Sell
34,548
-1,958
-5% -$97.5K 0.09% 124
2018
Q4
$1.9M Sell
36,506
-1,355
-4% -$72.8K 0.12% 109
2018
Q3
$2.35M Sell
37,861
-3,062
-7% -$182K 0.13% 100
2018
Q2
$2.27M Buy
40,923
+67
+0.2% +$3.62K 0.13% 97
2018
Q1
$2.58M Sell
40,856
-5,447
-12% -$350K 0.15% 88
2017
Q4
$2.84M Sell
46,303
-1,221
-3% -$76.4K 0.16% 82
2017
Q3
$3.03M Sell
47,524
-729
-2% -$42.6K 0.17% 80
2017
Q2
$2.69M Sell
48,253
-1,564
-3% -$85.1K 0.16% 82
2017
Q1
$2.71M Sell
49,817
-83
-0.2% -$4.55K 0.16% 83
2016
Q4
$2.92M Sell
49,900
-8,852
-15% -$484K 0.18% 77
2016
Q3
$3.17M Buy
58,752
+1,946
+3% +$125K 0.2% 73
2016
Q2
$4.18M Buy
56,806
+356
+0.6% +$25.2K 0.27% 67
2016
Q1
$3.61M Sell
56,450
-867
-2% -$54.7K 0.24% 69
2015
Q4
$3.94M Sell
57,317
-3,444
-6% -$228K 0.27% 66
2015
Q3
$3.6M Buy
60,761
+3,568
+6% +$226K 0.26% 68
2015
Q2
$3.81M Sell
57,193
-863
-1% -$56.9K 0.26% 67
2015
Q1
$3.75M Buy
58,056
+2,195
+4% +$137K 0.25% 68
2014
Q4
$3.3M Sell
55,861
-9,753
-15% -$550K 0.22% 70
2014
Q3
$3.36M Buy
65,614
+210
+0.3% +$10.5K 0.24% 71
2014
Q2
$3.17M Sell
65,404
-256
-0.4% -$12.6K 0.22% 72
2014
Q1
$3.41M Sell
65,660
-1,297
-2% -$69K 0.24% 71
2013
Q4
$3.56M Sell
66,957
-8,680
-11% -$442K 0.25% 72
2013
Q3
$3.5M Sell
75,637
-188
-0.2% -$8.25K 0.27% 70
2013
Q2
$3.39M Buy
+75,825
New +$3.29M 0.27% 67

Other funds holding BMY

Park National Corp's BMY Position: Q2 2026 in Review

Park National Corp reduced its Bristol-Myers Squibb (BMY) stake by 6.3% in Q2 2026, selling an estimated $66.3K and leaving 17,062 shares worth $983K. The position accounts for 0.03% of the portfolio, ranked #200.

Park National Corp first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.18M in Q2 2016. 895 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Park National Corp held 17,062 shares of Bristol-Myers Squibb worth $983K as of Q2 2026.
  • Park National Corp sold 1,155 Bristol-Myers Squibb shares in Q2 2026, an estimated $66.3K.
  • Bristol-Myers Squibb made up 0.03% of Park National Corp's portfolio in Q2 2026, its #200 holding.
  • Park National Corp first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Park National Corp's Bristol-Myers Squibb position peaked at $4.18M in Q2 2016.
  • 895 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Park National Corp's 13F filing for Q2 2026, filed 15 Jul 2026.